First test of new lupus drug begins in patients

NCT ID NCT07177911

Summary

This is the first human study of an experimental drug called CC312 for people with moderate-to-severe lupus. The main goal is to check the safety and side effects in 32 participants, and see how the body processes the drug. Researchers will also look for early signs that it might help control lupus disease activity.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SLE - SYSTEMIC LUPUS ERYTHEMATOSUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • West China Hospital, Sichuan University

    RECRUITING

    Chengdu, Sichuan, 610041, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.